CME Group Rating Lowered to Market Perform at Raymond James (CME)
CME Group (NYSE: CME) was downgraded by analysts at Raymond James (NYSE: RJF) from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Thursday.
Other equities research analysts have also recently issued reports about the stock. Analysts at JPMorgan Chase (NYSE: JPM) cut their price target on shares of CME Group from $270.00 to $263.00 in a research note to investors on Friday, April 27th. They now have a “neutral” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of CME Group in a research note to investors on Friday, April 27th. They now have a $288.00 price target on the stock. Finally, analysts at Barclays Capital (NYSE: BCS) cut their price target on shares of CME Group from $270.00 to $261.00 in a research note to investors on Friday, April 27th. They now have an “equal weight” rating on the stock.
CME Group traded up 2.88% on Thursday, hitting $260.881. CME Group has a 1-year low of $224.69 and a 1-year high of $304.61. The company has a market cap of $17.339 billion and a price-to-earnings ratio of 10.41.
CME Group last posted its quarterly earnings results on Thursday, April 26th. The company reported $4.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.03 by $0.01. The company’s revenue for the quarter was down 6.9% on a year-over-year basis. Analysts expect that CME Group will post $4.12 EPS next quarter.
CME Group Inc. (CME Group) offers a range of global products across all asset classes based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, metals, weather and real estate.